Novartis Deal Values Avidity Biosciences At $12 Billion

Core Insights - The acquisition is expected to increase Novartis' projected sales compound annual growth rate (CAGR) for the period 2024-2029 to 6% from the previous estimate of 5% [1] Company Summary - Novartis anticipates a rise in its expected sales CAGR due to the acquisition, indicating a positive outlook for future revenue growth [1]